| Literature DB >> 32455584 |
Yu-Chia Chang1, Kuei-Hung Lai1, Sunil Kumar2, Po-Jen Chen3, Yi-Hsuan Wu1, Ching-Long Lai1,4, Hsi-Lung Hsieh1,4,5, Ping-Jyun Sung6,7,8, Tsong-Long Hwang1,2,9,10,11.
Abstract
Octocoral Sinularia leptoclados has been identified as a source of bioactive 9,11-secosteroids. This study adopted a targeted isolation approach to the discovery and analysis of five 9,11-secosteroids, including two novel compounds named sinleptosterols A (1) and B (2) as well as five known analogues (8αH-3β,11-dihydroxy-24-methylene-9,11-secocholest-5-en-9-one (3), 8βH-3β,11-dihydroxy-24-methylene-9,11-secocholest-5-en-9-one (4), leptosterol A (5), (24S)-3β,11-dihydroxy-24-methyl-9,11-secocholest-5-en-9-one (6), and 3β,11-dihydroxy-9,11-secogorgost-5-en-9-one (7)) in terms of 1H-NMR patterns and potency against neutrophilic inflammation. The structure of secosteroids 1 and 2 was deduced from general spectroscopic analysis and an examination of NMR spectra. Among the above-mentioned isolates, compound 4 had the most pronounced effect in inhibiting elastase release and superoxide anion generation, with the IC50 values of 2.96 and 1.63 μM, respectively.Entities:
Keywords: Sinularia leptoclados; antineutrophilic inflammation; elastase; secosteroids; superoxide anion
Mesh:
Substances:
Year: 2020 PMID: 32455584 PMCID: PMC7281107 DOI: 10.3390/md18050271
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1The structures of 9,11-secosteroids sinleptosterols A (1) and B (2), 8αH-3β,11-dihydroxy-24-methylene-9,11-secocholest-5-en-9-one (3), 8βH-3β,11-dihydroxy-24-methylene-9,11-secocholest-5-en-9-one (4), leptosterol A (5), (24S)-3β,11-dihydroxy-24-methyl-9,11-secocholest-5-en-9-one (6), and 3β,11-dihydroxy-9,11-secogorgost-5-en-9-one (7), and a picture of S. leptoclados.
Figure 21H-NMR spectra of fractions derived from the EtOAc extract of octocoral S. leptoclados extract as well as their corresponding inhibitory effects on superoxide anion generation (SIC50) and elastase release (EIC50) in N-Formylmethionyl-leucyl-phenylalanine (fMLF)/cytochalasin B (CB)-induced human neutrophils. * Both SIC50 and EIC50 are over 10 μg/mL.
1H (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) NMR data and COSY and HMBC for 1.
| Position | δH ( | δC, Type | COSY | HMBC |
|---|---|---|---|---|
| 1a/b | 1.50 m; 1.81 m | 31.0, CH2 | H2-2 | C-3 |
| 2a/b | 1.40 m; 1.93 m | 30.8, CH2 | H2-1, H-3 | n. o. a |
| 3 | 3.51 m | 71.4, CH | H2-2, H2-4 | n. o. |
| 4a/b | 2.23 m; 2.44 m | 40.6, CH2 | H-3 | C-3, C-5, C-6 |
| 5 | - | 140.4, C | - | - |
| 6 | 5.47 brd (5.6) | 121.5, CH | H2-7 | C-4, C-7, C-8, C-10 |
| 7a/b | 1.98 m; 2.40 m | 33.1, CH2 | H-6, H-8 | C-5, C-6 |
| 8 | 3.03 ddd (12.4, 12.4, 6.8) | 43.8, CH | H2-7, H-14 | C-7, C-9, C-14 |
| 9 | - | 217.5, C | - | - |
| 10 | - | 48.4, C | - | - |
| 11a/b | 3.86 m; 3.74m | 59.4, CH2 | H2-12 | n. o. |
| 12 | 1.33 m; 1.67 m | 40.2, CH2 | H2-11 | C-11, C-13 |
| 13 | - | 45.5, C | - | - |
| 14 | 2.61 m | 42.1, CH | H-8, H2-15 | C-9 |
| 15 | 1.31 m; 1.58 m | 24.6, CH2 | H-14, H2-16 | C-14 |
| 16 | 1.31 m; 1.71 m | 24.8, CH2 | H2-15, H-17 | n. o. |
| 17 | 1.78 m | 49.6, CH | H2-16, H-20 | n. o. |
| 18 | 0.69 s | 17.7, CH3 | - | C-12, C-13, C-14, C-17 |
| 19 | 1.40 s | 22.8, CH3 | - | C-1, C-5, C-9, C-10 |
| 20 | 2.25 m | 38.5, CH | H-17, H3-21, H-22 | C-16 |
| 21 | 1.08 d (6.4) | 22.1, CH3 | H-20 | C-17, C-20 |
| 22 | 5.65 dd (16.0, 7.2) | 134.6, CH | H-20, H-23 | C-20, C-21, C-24 |
| 23 | 5.93 d (16.0) | 130.2, CH | H-22 | C-20, C-24, C-25, C-28 |
| 24 | - | 153.0, C | - | |
| 25 | 2.54 m | 29.4, CH | H3-26, H3-27 | C-24, C-28 |
| 26 | 1.06 d (6.8) | 22.4, CH3 | H-25 | C-24, C-25 |
| 27 | 1.07 d (6.8) | 21.5, CH3 | H-25 | C-24, C-25 |
| 28 | 4.83 d (6.8) | 109.8, CH2 | C-24, C-25 |
a n. o. = not observed.
Figure 3Selected NOESY correlations observed for 1.
1H (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) NMR data and COSY and HMBC for 2.
| Position | δH ( | δC, Type | COSY | HMBC |
|---|---|---|---|---|
| 1a/b | 1.53 m; 1.90 m | 30.8, CH2 | H2-2 | n. o. a |
| 2a/b | 1.31 m; 1.93 m | 31.3, CH2 | H2-1, H-3 | n. o. |
| 3 | 3.51 m | 71.4, CH | H2-2, H2-4 | n. o. |
| 4a/b | 2.23 m; 2.44 m | 40.6, CH2 | H-3 | n. o. |
| 5 | - | 140.4, C | - | - |
| 6 | 5.48 brd (5.6) | 121.5, CH | H2-7 | C-4, C-7, C-8 |
| 7a/b | 2.02 m; 2.39 m | 33.0, CH2 | H-6, H-8 | n. o. |
| 8 | 3.03 td (12.4, 6.8) | 43.6, CH | H2-7, H-14 | C-7, C-9, C-14 |
| 9 | - | 217.5, C | - | - |
| 10 | - | 48.5, C | - | - |
| 11a/b | 3.69 m; 3.83m | 59.4, CH2 | H2-12 | n. o. |
| 12 | 1.32 m; 1.68 m | 40.3, CH2 | H2-11 | n. o. |
| 13 | - | 45.6, C | - | - |
| 14 | 2.61 m | 41.8, CH | H-8, H2-15 | n. o. |
| 15 | 1.30 m; 1.56 m | 24.4, CH2 | H-14, H2-16 | n. o. |
| 16 | 1.30 m; 1.74 m | 25.0, CH2 | H2-15, H-17 | - |
| 17 | 1.65 m | 49.2, CH | H2-16 | - |
| 18 | 0.67 s | 17.3, CH3 | - | C-11, C-12, C-13, C-14, C-17 |
| 19 | 1.38 s | 22.9, CH3 | - | C-1, C-5, C-9, C-10 |
| 20 | 1.41 m | 34.0, CH | H3-21 | n. o. |
| 21 | 1.01 d (6.8) | 19.4, CH3 | H-20 | C-17, C-20, C-22 |
| 22 | 1.17 m; 1.51 m | 34.7, CH2 | H-23 | n. o. |
| 23 | 1.81 m; 2.39 m | 31.0, CH2 | H-22 | n. o. |
| 24 | - | 148.5, C | - | |
| 25 | - | 142.7, C | - | |
| 26 | 4.59 d (1.2) | 112.5, CH2 | - | C-25 |
| 27 | 1.90 s | 21.2, CH3 | - | C-24, C-25, C-26 |
| 28 | 5.06 s | 112.0, CH2 | - | C-23, C-24, C-25 |
a n. o. = not observed.
Effects of compounds 1–7 on superoxide anion generation and elastase release in fMLF/CB-induced human neutrophils.
| Compound | Superoxide Anions | Elastase Release | ||
|---|---|---|---|---|
| IC50 (μM) a | Inh % | IC50 (μM) | Inh % | |
|
| 7.07 ± 0.52 | 64.76 ± 3.42 *** | 7.57 ± 0.40 | 65.04 ± 2.76 *** |
|
| 4.68 ± 0.57 | 76.30 ± 5.09 *** | 4.29 ± 0.25 | 105.09 ± 5.25 *** |
|
| 1.97 ± 0.12 | 90.47 ± 2.44 *** | 3.12 ± 0.07 | 112.23 ±5.01 *** |
|
| 2.96 ± 0.91 | 91.11 ± 4.51 *** | 1.63 ± 0.15 | 93.74 ± 1.23 *** |
|
| 8.07 ± 0.53 | 57.93 ± 2.30 *** | 4.73 ± 0.57 | 86.32 ± 2.91 *** |
|
| 4.09 ± 0.50 | 60.51 ± 4.06 *** | >10 | 25.38 ± 6.68 ** |
|
| >10 | 10.29 ± 5.42 *** | >10 | 18.87 ± 3.86 *** |
Percentage of inhibition (Inh %) at 10 μM concentration. Results are presented as mean ± S.E.M. (n = 3 or 4). ** p < 0.01, *** p < 0.001 compared with the control (DMSO). a Concentration necessary for 50% inhibition (IC50).
Figure 4FPR1 receptor binding assay of compounds 1–7 in human neutrophils. Data are representative of three experiments. ** p < 0.01, *** p < 0.001 versus the control group.